Imprimis Pharmaceuticals has entered in an equipment lease agreement with Essex Capital Corporation, which provided Imprimis with gross proceeds of $2 million. The agreement covers the sale and leaseback of Imprimis’ drug manufacturing equipment and has an initial term of up to three years, with an additional one-year lease extension, subject to Imprimis achieving certain financial milestones. Imprimis has made significant upgrades and additions to the company’s compounding equipm...